Related Experiment Video
Updated: Aug 9, 2026

Multicellular Human Alveolar Model Composed of Epithelial Cells and Primary Immune Cells for Hazard Assessment
Published on: May 6, 2020
Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers
Insights
Hepatitis B vaccine and immunoglobulin effectively prevent hepatitis B infection in newborns born to HBsAg-positive mothers. These interventions demonstrate significant benefits with a good safety profile, reducing infection rates substantially.
Area of Science:
- Immunology
- Vaccinology
- Neonatal Medicine
Background:
- Neonatal transmission of Hepatitis B virus (HBV) from HBsAg-positive mothers poses a significant health risk.
- Hepatitis B vaccine and hepatitis B immunoglobulin are established interventions to prevent perinatal HBV infection.
Purpose of the Study:
- To evaluate the efficacy and safety of hepatitis B vaccines and hepatitis B immunoglobulin in preventing HBV infection in infants born to HBsAg-positive mothers.
- To compare different vaccine types (plasma-derived vs. recombinant) and immunoglobulin combinations.
Main Methods:
- Systematic review and meta-analysis of 29 randomized clinical trials.
- Primary outcome: Hepatitis B occurrence confirmed by blood specimen.
- Subgroup analyses based on trial quality, maternal HBeAg status, and timing of immunisation.
Main Results:
- Hepatitis B vaccine significantly reduced HBV occurrence compared to placebo/no intervention (RR 0.28, 95% CI 0.20-0.40).
- Hepatitis B immunoglobulin and combined vaccine plus immunoglobulin also demonstrated significant protective effects.
- No significant differences were found between recombinant and plasma-derived vaccines, or varying vaccine doses.
Conclusions:
- Hepatitis B vaccine, hepatitis B immunoglobulin, and their combination are effective in preventing hepatitis B infection in newborns of HBsAg-positive mothers.
- The interventions appear safe, although comprehensive adverse event data were limited in the reviewed trials.
Background:
Hepatitis B vaccine and hepatitis B immunoglobulin are considered for newborn infants of HBsAg-positive mothers to prevent hepatitis B infection.
Objectives:
To assess the beneficial and harmful effects of hepatitis B vaccines and hepatitis B immunoglobulin in newborn infants of HBsAg-positive mothers.
Search Strategy:
Trials were identified through The Cochrane Neonatal Group Controlled Trials Register, The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials in The Cochrane Library, MEDLINE, and EMBASE (until February 2004), authors of trials, and pharmaceutical companies.
Selection Criteria:
Randomised clinical trials comparing: plasma-derived vaccine (PDV) or recombinant vaccine (RV) versus no intervention, placebo, or other active vaccines; hepatitis B immunoglobulin versus no intervention, placebo, or other control immunoglobulin; as well as PDV or RV plus hepatitis B immunoglobulin versus no intervention, placebo, or other control vaccines or immunoglobulin.
Data Collection And Analysis:
Outcomes are assessed at maximal follow-up. The primary outcome measure was hepatitis B occurrence, based on a blood specimen positive for HBsAg, HBeAg, or antibody to hepatitis B core antigen (anti-HBc). Binary outcomes are reported as relative risks (RR) with 95% confidence interval (CI). Subgroup analyses were performed with regard to methodological quality of the trial, mother's HBe-Ag status, and time of immunisation after birth.
Main Results:
We identified 29 randomised clinical trials, five of which were considered high quality. Only three trials reported inclusion of hepatitis B e-antigen negative mothers. Compared with placebo/no intervention, vaccine reduced hepatitis B occurrence (RR 0.28, 95% confidence interval (CI) 0.20 to 0.40, 4 trials). No significant differences of hepatitis B occurrence were found comparing recombinant vaccine (RV) versus plasma-derived vaccine (PDV) (RR 1.00, 95% CI 0.71 to 1.42, 4 trials) and high-dose versus low-dose vaccine (PDV: RR 0.97, 95% CI 0.55 to 1.68, 3 trials; RV: RR 0.78, 95% CI 0.31 to 1.94, 1 trial). Compared with placebo/no intervention, hepatitis B immunoglobulin or the combination of vaccine plus hepatitis B immunoglobulin reduced hepatitis B occurrence (hepatitis B immunoglobulin: RR 0.50, 95% CI 0.41 to 0.60, 1 trial; PDV plus hepatitis B immunoglobulin: RR 0.08, 95% CI 0.03 to 0.17, 3 trials). Compared with vaccine, vaccine plus hepatitis B immunoglobulin reduced hepatitis B occurrence (RR 0.54, 95% CI 0.41 to 0.73, 10 trials). Hepatitis B vaccine and hepatitis B immunoglobulin seem safe, but few trials reported on adverse events.
Authors' Conclusions:
Vaccine, hepatitis B immunoglobulin, and vaccine plus hepatitis B immunoglobulin prevent hepatitis B occurrence in newborn infants of HBsAg positive mothers.
Related Concept Videos
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Hepatitis
Viral Hepatitis I: Introduction
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Development of the Oral Microbiota
